IPA vs. ACXP, THTX, CASI, VYNE, VIRX, NRXP, DARE, FBIO, APRE, and LEXX
Should you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Acurx Pharmaceuticals (ACXP), Theratechnologies (THTX), CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), Viracta Therapeutics (VIRX), NRx Pharmaceuticals (NRXP), Daré Bioscience (DARE), Fortress Biotech (FBIO), Aprea Therapeutics (APRE), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical preparations" industry.
Acurx Pharmaceuticals (NASDAQ:ACXP) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
Acurx Pharmaceuticals has a beta of -1.9, indicating that its stock price is 290% less volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.
Acurx Pharmaceuticals received 3 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. Likewise, 90.91% of users gave Acurx Pharmaceuticals an outperform vote while only 87.50% of users gave ImmunoPrecise Antibodies an outperform vote.
11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 35.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Acurx Pharmaceuticals has a net margin of 0.00% compared to Acurx Pharmaceuticals' net margin of -60.23%. Acurx Pharmaceuticals' return on equity of -26.54% beat ImmunoPrecise Antibodies' return on equity.
Acurx Pharmaceuticals currently has a consensus price target of $12.00, suggesting a potential upside of 494.06%. ImmunoPrecise Antibodies has a consensus price target of $7.00, suggesting a potential upside of 473.77%. Given ImmunoPrecise Antibodies' higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than ImmunoPrecise Antibodies.
In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 1 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.
Acurx Pharmaceuticals has higher earnings, but lower revenue than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Acurx Pharmaceuticals beats ImmunoPrecise Antibodies on 9 of the 15 factors compared between the two stocks.
Get ImmunoPrecise Antibodies News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunoPrecise Antibodies Competitors List
Related Companies and Tools
